Antibody Directed Enzyme Prodrug Therapy (ADEPT): Trials and Tribulations

Publication date: Available online 12 September 2017
Source:Advanced Drug Delivery Reviews
Author(s): Surinder K. Sharma, Kenneth D. Bagshawe
Antibody directed enzyme prodrug therapy has the potential to be an effective therapy for most common solid cancers. Clinical studies with CPG2 system have shown the feasibility of this approach. The key limitation has been immunogenicity of the enzyme. Technologies now exist to eliminate this problem. Non-immunogenic enzymes in combination with prodrugs that generate potent cytotoxic drugs can provide a powerful approach to cancer therapy. ADEPT has the potential to be non -toxic to normal tissue and can therefore be combined with other modalities including immunotherapy for greater clinical benefit.



http://ift.tt/2jn3YFM